High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

Simona Sica, Roelof Willemze, Stefan Suciu, Giovanna Meloni, Boris Labar, Jean-Pierre Marie, Constantijn J. M. Halkes, Petra Muus, Martin Mistrik, Sergio Amadori, Giorgina Specchia, Francesco Fabbiano, Francesco Nobile, Marco Sborgia, Andrea Camera, Dominik L. D. Selleslag, Francois Lefrer̀E Sr., Domenico Magro, Nicola Cantore, Meral BeksacZwi Berneman, Xavier Thomas, Lorella Melillo, Jose E. Guimaraes, Pietro Leoni, Mario Luppi, Maria E. Mitra, Dominique Bron, Georges Fillet, Erik W. A. Marijt, Adriano Venditti, Anne Hagemeijer, Marco Mancini, Joop Jansen, Daniela Cilloni, Liv Meert, Paola Fazi, Marco Vignetti, Silvia M. Trisolini, Franco Mandelli, Theo De Witte

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.
Original languageEnglish
Pages (from-to)219-228
Number of pages10
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume32
DOIs
Publication statusPublished - 2014

Keywords

  • leukemia

Fingerprint

Dive into the research topics of 'High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial'. Together they form a unique fingerprint.

Cite this